TGI-5 / TG ImmunoPharma - LARVOL DELTA

Evolution and structural diversity of the MotAB stator: insights into the origins of bacterial flagellar motility. (PubMed, mBio) - "TGI5 motors, such as those found in the Escherichia coli K12 system, are primarily restricted to Pseudomonadota, whereas TGI4 motors, such as the Na+-powered polar motors of Vibrio (PomAB), are distributed across a broader range of bacterial lineages...This study uses a comparative approach that integrates phylogenetics, 3D protein structure, motility assays, and ancestral state reconstruction (ASR) to provide insights into the structural mechanisms that first powered the flagellar motor. We provide the first phylogenetic and structural characterization and classification of MotAB and relatives."

Journal

Effect of TT-816, a novel immune response modifier targeting cannabinoid CB2 receptor, on antitumor immunity and cancer growth. (ASCO 2024) - "By contrast, anti-PD1 had little effect (TGI 5%). TT-816 is a novel, oral small molecule immune response modifier that selectively blocks CB2R on immune cells and cancer cells. Preclinical data have demonstrated that it stimulates antitumor immune response and inhibits cancer growth in both hot and cold tumor models. TT-816 is currently undergoing phase 1 clinical trials for the treatment of a broad range of solid tumors."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD4 • CD86 • IFNG • IL12A • TNFA

Tiangang Yinuo TGI-5 monoclonal antibody obtained clinical trial approval from the U.S. FDA [Google translation] (PRNewswire-Asia) - "...the monoclonal antibody drug (project code TGI-5) independently developed by Hefei Tiangang Immunopharmaceutical Co., Ltd. (Tiangang Yinuo) obtained the U.S. Food and Drug Administration (FDA) clinical trial (IND) clearance."

IND • Oncology